Barinthus Biotherapeutics (NASDAQ:BRNS) PT Lowered to $3.00

Barinthus Biotherapeutics (NASDAQ:BRNS) had its target price lowered by Barclays from $7.00 to $3.00 in a report issued on Thursday, Benzinga reports. Barclays currently has an overweight rating on the stock.

Separately, HC Wainwright restated a buy rating and issued a $8.00 target price on shares of Barinthus Biotherapeutics in a report on Friday, June 7th.

Barinthus Biotherapeutics Stock Performance

Shares of NASDAQ BRNS opened at $1.83 on Thursday. The stock has a fifty day moving average price of $2.35 and a two-hundred day moving average price of $2.73. The firm has a market cap of $71.42 million, a P/E ratio of -0.99 and a beta of -0.46. Barinthus Biotherapeutics has a 1 year low of $1.64 and a 1 year high of $5.10.

Barinthus Biotherapeutics (NASDAQ:BRNS) last announced its quarterly earnings data on Monday, May 13th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.24. On average, research analysts predict that Barinthus Biotherapeutics will post -2.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Barinthus Biotherapeutics

A hedge fund recently bought a new stake in Barinthus Biotherapeutics stock. DC Funds LP acquired a new stake in shares of Barinthus Biotherapeutics plc (NASDAQ:BRNS) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 642,204 shares of the company’s stock, valued at approximately $1,528,000. Barinthus Biotherapeutics makes up 14.8% of DC Funds LP’s investment portfolio, making the stock its 3rd biggest position. DC Funds LP owned 1.65% of Barinthus Biotherapeutics as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 25.20% of the company’s stock.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.